On July 6, WuXi XDC rose 3.89% in regular trading, trading at HK$64.8/share, with turnover of HK$178 million. The stock continued its upward momentum as the CXO sector extended its recent rally.

On the news front, the broader CXO sector maintained strong performance, with peer stocks GenScript Biotech up 5.88%, XtalPi up 4.18%, and WuXi Biologics up 2.34%, reflecting significant sector linkage. The company previously announced a share buyback plan of up to US$100 million using internal funds, with its appointed trustee having purchased 5.7 million shares at an average price of HK$57.3 during May, spending approximately HK$327 million. BOCOM International listed WuXi XDC as a top pick among high-growth CDMO players, while Guotai Junan International maintained an Outperform rating with a target price of HK$84.38. The company reported 2025 revenue of RMB 5.94 billion, up 46.6% year-over-year, with unfilled orders of approximately US$1.489 billion, up 50.3%, underpinning strong earnings visibility.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)